Herbal medicine for diarrhea from irinotecan chemo
Part of Cancer clinical trials.
This study tests if a Chinese herbal formula (XCHT) can reduce diarrhea caused by the chemo drug irinotecan. If you are getting irinotecan and already had troublesome diarrhea, you may be able to join and get supportive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer diagnosis (by biopsy or other tests).
- You are between 18 and 75 years old.
- You had moderate or worse diarrhea from irinotecan chemotherapy within the last month.
- You plan to have at least 3 more cycles of irinotecan chemo.
- Your blood counts, liver, and kidney function are good enough for chemo.
- You are able to fill out study questionnaires and follow instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill made from a harmless bacteria can prevent diarrhea caused by certain chemotherapy treatments. It is for people with advanced colorectal cancer or breast cancer who are about to start specific treatments.
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
This study looks at whether your body type according to traditional Chinese medicine (TCM) can predict diarrhea caused by combining immunotherapy and targeted therapy for liver cancer. The goal is to help doctors better manage and prevent this side effect.
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
This trial tests a “microbiome health” product (a probiotic-type supplement) to improve how well irinotecan chemotherapy works for people with metastatic colon cancer. It aims to support gut health so treatment can be delivered effectively.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Hear when a new Xiao Chai Hu Tang trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.